Drugs / Idrabiotaparinux sodium
last change Jan 2011 re-read 2 minutes ago

Idrabiotaparinux sodium

targets F10 via inhibition

Developed for
venous thromboembolism · atrial fibrillation · pulmonary embolism
Investigated by
Sanofi

Trials 3 · a red edge is where a trial was stopped

2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 3 NCT00580216 Dec 2007 → Oct 2010 atrial fibrillation Sanofi Terminated No outcome recorded
Phase 3 NCT00345618 Jun 2006 → Oct 2010 pulmonary embolism, venous thromboembolism Sanofi Completed No outcome recorded
Phase 3 NCT00311090 Apr 2006 → Jan 2008 venous thromboembolism Sanofi Completed No outcome recorded

Evidence & citations 9 cited values

Every value below carries the sentence it was read from. 5 sources stand behind the page.

FieldValueCited text
Known as Idrabiotaparinux sodium “Objectives are to evaluate whether idrabiotaparinux sodium (SSR126517E) is as least as effective as a standard warfarin treatment to prevent recurrence of venous thromboembolic...” NCT00345618
1

“once weekly subcutaneous (SC) injection of idrabiotaparinux sodium (biotinylated idraparinux)” NCT00580216

Known as Idrabiotaparinux ClinicalTrials.gov intervention name — accepted as the source's own label NCT00580216
2

NCT00345618

NCT00311090

Known as Idrabiotaparinux sodico ChEMBL registry synonym — accepted as the source's own label CHEMBL4297768
Known as Idrabiotaparinux sodique ChEMBL registry synonym — accepted as the source's own label CHEMBL4297768
Known as Ssr-126517 sodium ChEMBL registry synonym — accepted as the source's own label CHEMBL4297768
Known as SSR126517E “Objectives are to evaluate whether idrabiotaparinux sodium (SSR126517E) is as least as effective as a standard warfarin treatment to prevent recurrence of venous thromboembolic...” NCT00345618
Action Inhibit “Idrabiotaparinux has a similar time course of FXa inhibition, efficacy and safety to idraparinux for the treatment of deep venous thrombosis.” PMID 20946157 Jan 2011
1

“Coagulation factor X inhibitor” CHEMBL4297768

Route Subcutaneous “both given subcutaneously” PMID 20946157 Jan 2011
Target F10 “Coagulation factor X inhibitor” CHEMBL4297768